Immunic (IMUX) Change in Cash (2013 - 2026)

Immunic (IMUX) has 14 years of Change in Cash data on file, last reported at $171.1 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Cash rose 901.1% year-over-year to $171.1 million; the trailing twelve-month figure through Mar 2026 stood at $172.3 million (up 307.6% YoY), and the FY2025 full-year result was -$20.2 million, down 83.4% from the prior year.
• Change in Cash grew to $171.1 million in Q1 2026, from -$19.6 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $171.1 million in Q1 2026 to a low of -$23.4 million in Q4 2024.
• A 5-year average of $5.9 million and a median of -$15.3 million in 2022 frame the typical range for Change in Cash.
• Across the five-year window, Change in Cash sank 258.06% in 2023 and soared 901.1% in 2026, its largest moves.
• Tracing IMUX's Change in Cash over 5 years: stood at $34.0 million in 2022, then slumped by 138.31% to -$13.0 million in 2023, then sank by 79.82% to -$23.4 million in 2024, then climbed by 16.04% to -$19.6 million in 2025, then soared by 971.02% to $171.1 million in 2026.
• Business Quant data shows IMUX's Change in Cash at $171.1 million in Q1 2026, -$19.6 million in Q4 2025, and -$20.2 million in Q3 2025.